Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma

被引:832
作者
Keats, Jonathan J.
Fonseca, Rafael [1 ]
Chesi, Marta
Schop, Roelandt
Baker, Angela
Ching, Wee-Joo
Van Wier, Scott
Tiedemann, Rodger
Shi, Chang-Xin
Sebag, Michael
Braggio, Esteban
Henry, Travis
Zhu, Yuan-Xiao
Fogle, Homer
Price-Troska, Tammy
Ahmann, Gregory
Mancini, Catherine
Brents, Leslie A.
Kumar, Shaji
Greipp, Philip
Dispenzieri, Angela
Bryant, Barb
Mulligan, George
Bruhn, Laurakay
Barrett, Michael
Valdez, Riccardo
Trent, Jeff
Stewart, A. Keith
Carpten, John
Bergsagel, P. Leif
机构
[1] Mayo Clin Arizona, Ctr Comprehens Canc, Scottsdale, AZ 85259 USA
[2] Mayo Clin, Rochester, MN 55905 USA
[3] Translat Genom, Hematolog Malignancies Res Unit, Phoenix, AZ 85004 USA
[4] Agilent Technol, Santa Clara, CA 95051 USA
[5] Millennium Pharmaceut, Cambridge, MA 02139 USA
[6] Natl Canc Ctr, Genet Branch, Bethesda, MD 20889 USA
关键词
D O I
10.1016/j.ccr.2007.07.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of NF-kappa B has been noted in many tumor types, however only rarely has this been linked to an underlying genetic mutation. An integrated analysis of high-density oligonucleotide array CGH and gene expression profiling data from 155 multiple myeloma samples identified a promiscuous array of abnormalities contributing to the dysregulation of NF-kappa B in approximately 20% of patients. We report mutations in ten genes causing the inactivation of TRAF2, TRAF3, CYLD, cIAP1/cIAP2 and activation of NFKB1, NFKB2, CD40, LTBR, TACI, and NIK that result primarily in constitutive activation of the noncanonical NF-kappa B pathway, with the single most common abnormality being inactivation of TRAF3. These results highlight the critical importance of the NF-kappa B pathway in the pathogenesis of multiple myeloma.
引用
收藏
页码:131 / 144
页数:14
相关论文
共 37 条
[1]   Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA [J].
Barrett, MT ;
Scheffer, A ;
Ben-Dor, A ;
Sampas, N ;
Lipson, D ;
Kincaid, R ;
Tsang, P ;
Curry, B ;
Baird, K ;
Meltzer, PS ;
Yakhini, Z ;
Bruhn, L ;
Laderman, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (51) :17765-17770
[2]   Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM ;
Zhan, FH ;
Sawyer, J ;
Barlogie, B ;
Shaughnessy, J .
BLOOD, 2005, 106 (01) :296-303
[3]   Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma [J].
Bergsagel, PL ;
Chesi, M ;
Nardini, E ;
Brents, LA ;
Kirby, SL ;
Kuehl, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13931-13936
[4]   Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses [J].
Caamaño, JH ;
Rizzo, CA ;
Durham, SK ;
Barton, DS ;
Raventós-Suárez, C ;
Snapper, CM ;
Bravo, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (02) :185-196
[5]   High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients [J].
Carrasco, DR ;
Tonon, G ;
Huang, YS ;
Zhang, YY ;
Sinha, R ;
Bin, F ;
Stewart, JP ;
Zhan, FG ;
Khatry, D ;
Protopopova, M ;
Protopopov, A ;
Sukhdeo, K ;
Hanamura, I ;
Stephens, O ;
Barlogie, B ;
Anderson, KC ;
Chin, L ;
Shaughnessy, JD ;
Brennan, C ;
DePinho, RA .
CANCER CELL, 2006, 9 (04) :313-325
[6]   Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts [J].
Ciana, P ;
Neri, A ;
Cappellini, C ;
Cavallo, F ;
Pomati, M ;
Chang, CC ;
Maiolo, AT ;
Lombardi, L .
ONCOGENE, 1997, 14 (15) :1805-1810
[7]   Mutations in the NF-κB signaling pathway:: implications for human disease [J].
Courtois, G. ;
Gilmore, T. D. .
ONCOGENE, 2006, 25 (51) :6831-6843
[8]   The alternative NF-κB pathway from biochemistry to biology:: Pitfalls and promises for future drug development [J].
Dejardin, Emmanuel .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (09) :1161-1179
[9]   The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma [J].
Fonseca, R ;
Debes-Marun, CS ;
Picken, EB ;
Dewald, GW ;
Bryant, SC ;
Winkler, JM ;
Blood, E ;
Oken, MM ;
Santana-Dávila, R ;
González-Paz, N ;
Kyle, RA ;
Gertz, MA ;
Dispenzieri, A ;
Lacy, MQ ;
Greipp, PR .
BLOOD, 2003, 102 (07) :2562-2567
[10]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575